MiNK Therapeutics, Inc. (INKT), a clinical-stage biopharmaceutical company, Thursday announced that it has received formal notice from Nasdaq confirming its regained compliance with the listing requirements for the Nasdaq Capital Market.
The company has now met both the minimum bid price and market value of listed securities requirements, addressing the issues previously raised by Nasdaq.
With this development, MiNK Therapeutics has resolved the matter, and the company continues to meet all Nasdaq listing standards.
Currently, INKT is trading at $9.81, up by 3.33 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.